Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [11] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    Ando, Kenju
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Kawamura, Yukino
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
  • [12] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
    Fisher, B
    Dignam, J
    Wolmark, N
    DeCillis, A
    Emir, B
    Wickerham, DL
    Bryant, J
    Dimitrov, NV
    Abramson, N
    Atkins, JN
    Shibata, H
    Deschenes, L
    Margolese, RG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (22): : 1673 - 1682
  • [13] Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
    Albain, Kathy S.
    Gray, Robert J.
    Makower, Della F.
    Faghih, Amir
    Hayes, Daniel F.
    Geyer, Charles E., Jr.
    Dees, Elizabeth C.
    Goetz, Matthew P.
    Olson, John A., Jr.
    Lively, Tracy
    Badve, Sunil S.
    Saphner, Thomas J.
    Wagner, Lynne, I
    Whelan, Timothy J.
    Ellis, Matthew J.
    Wood, William C.
    Keane, Maccon M.
    Gomez, Henry L.
    Reddy, Pavan S.
    Goggins, Timothy F.
    Mayer, Ingrid A.
    Brufsky, Adam M.
    Toppmeyer, Deborah L.
    Kaklamani, Virginia G.
    Berenberg, Jeffrey L.
    Abrams, Jeffrey
    Sledge, George W., Jr.
    Sparano, Joseph A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (04): : 390 - 399
  • [15] Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
    Kelly, Catherine Margaret
    Crown, John
    Russell, Niamh
    Barron, Stephen
    Lynch, Seodhna
    O'Grady, Anthony
    Sheehan, Katherine
    Fay, Joanna
    Amberger-Murphy, Verena
    Saha, Anurati
    Loughman, Tony
    Dynoodt, Peter
    Fender, Bozena
    Ruiz, Cesar Lopez
    Wang, Chan-Ju Angel
    O'Leary, Desmond
    O'Connor, Darran
    Gallagher, William M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [16] Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer
    Choi, Woo Jung
    Sim, Hayan
    Kim, Hee Jeong
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Kim, Hak Hee
    ACTA RADIOLOGICA, 2021, 62 (12) : 1592 - 1600
  • [17] The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer
    Kristin E. Rojas
    Donna-Marie Manasseh
    Mary Rojas
    Andrea Mattocks
    Leah Portnow
    Sarah Kantharia
    Natalie Zelenko
    Christina Giuliano
    Patrick I. Borgen
    Breast Cancer Research and Treatment, 2020, 182 : 79 - 83
  • [18] The Evolving Use of SERDs in Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeselsohn, Rinath M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 428 - 431
  • [19] Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
    Nederlof, I
    Hajizadeh, S.
    Sobhani, F.
    Raza, S. E. A.
    AbdulJabbar, K.
    Harkes, R.
    van de Vijver, M. J.
    Salgado, R.
    Desmedt, C.
    Kok, M.
    Yuan, Y.
    Horlings, H. M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [20] Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
    I. Nederlof
    S. Hajizadeh
    F. Sobhani
    S. E. A. Raza
    K. AbdulJabbar
    R. Harkes
    M. J. van de Vijver
    R. Salgado
    C. Desmedt
    M. Kok
    Y. Yuan
    H. M. Horlings
    npj Breast Cancer, 8